Zobrazeno 1 - 10
of 1 715
pro vyhledávání: '"John Crown"'
Autor:
Neil T Conlon, Sandra Roche, Amira F Mahdi, Alacoque Browne, Laura Breen, Johanna Gaubatz, Justine Meiller, Fiona O'Neill, Lorraine O'Driscoll, Mattia Cremona, Bryan T Hennessy, Lisa D Eli, John Crown, Denis M Collins
Publikováno v:
Translational Oncology, Vol 49, Iss , Pp 102073- (2024)
Background: HER2-targeted therapies have revolutionised the treatment of HER2-positive breast cancer. However, de novo resistance or the emergence of acquired resistance is a persistent clinical problem. Here we report that neratinib, an irreversible
Externí odkaz:
https://doaj.org/article/80c2e8e9bf2e4172bafb263c57f5769f
Publikováno v:
Translational Oncology, Vol 46, Iss , Pp 102025- (2024)
New treatments are urgently required for triple-negative breast cancer (TNBC). As TP53 is mutated in approximately 80% of TNBC, it is theoretically an attractive target for new drugs for this disease. Arsenic trioxide (ATO), which is used to treat pr
Externí odkaz:
https://doaj.org/article/75039994030f4ff8baa64d4d87ad5977
Autor:
Claire Corcoran, Sweta Rani, Susan Breslin, Martina Gogarty, Irene M Ghobrial, John Crown, Lorraine O’Driscoll
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/bac0adf778b6420686bb18b3b8779958
Autor:
Rosalba Miceli, Hanna Eriksson, Giuseppe Lo Russo, Salvatore Alfieri, Maria Moksnes Bjaanæs, Filippo Pietrantonio, Loris De Cecco, Arsela Prelaj, Claudia Proto, Johan Franzén, Deirdre McDonnell, José Javier Berenguer Pina, Teresa Beninato, Laura Mazzeo, Patrizia Giannatempo, Elena Verzoni, John Crown, Åslaug Helland, Alexander Eustace
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background: Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in various cancers. ICI treatment is associated with the incidence of immune-related adverse events (irAEs) which can affect any organ. Data on irAEs occurrence in r
Externí odkaz:
https://doaj.org/article/104cb507efb6499da6d34e4000166944
Autor:
Nicola Cosgrove, Alex J. Eustace, Peter O’Donovan, Stephen F. Madden, Bruce Moran, John Crown, Brian Moulton, Patrick G. Morris, Liam Grogan, Oscar Breathnach, Colm Power, Michael Allen, Janice M. Walshe, Arnold D. Hill, Anna Blümel, Darren O’Connor, Sudipto Das, Małgorzata Milewska, Joanna Fay, Elaine Kay, Sinead Toomey, Bryan T. Hennessy, Simon J. Furney
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-16 (2023)
Abstract HER2-positive (HER2+) breast cancer accounts for 20–25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments i
Externí odkaz:
https://doaj.org/article/2aa94f4a6ce8446ea48464a6049912d0
Autor:
Martina S. J. McDermott, Brigid C. Browne, Neil T. Conlon, Neil A. O’Brien, Dennis J. Slamon, Michael Henry, Paula Meleady, Martin Clynes, Paul Dowling, John Crown, Norma O’Donovan
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/e0d45aa2e7a441378b538287bcf79ac3
Autor:
Dennis J. Slamon, Peter A. Fasching, Sara Hurvitz, Stephen Chia, John Crown, Miguel Martín, Carlos H. Barrios, Aditya Bardia, Seock-Ah Im, Denise A. Yardley, Michael Untch, Chiun-Sheng Huang, Daniil Stroyakovskiy, Binghe Xu, Rebecca L. Moroose, Sherene Loi, Frances Visco, Valerie Bee-Munteanu, Karen Afenjar, Rodrigo Fresco, Tetiana Taran, Arunava Chakravartty, Juan Pablo Zarate, Agnes Lteif, Gabriel N. Hortobagyi
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Ribociclib has demonstrated a statistically significant overall survival benefit in pre- and postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer. Ne
Externí odkaz:
https://doaj.org/article/73d02bee3f9e4dc6a76bef48c3ed8ce0
Autor:
Sandra Roche, Patricia Gaule, Deirdre Winrow, Nupur Mukherjee, Fiona O'Neill, Neil T Conlon, Justine Meiller, Denis M Collins, Alexandra Canonici, Mohammed Ibrahim Fawsi, Alejandra Estepa-Fernández, Stephen F Madden, John Crown, Norma O'Donovan, Alex J Eustace
Publikováno v:
PLoS ONE, Vol 18, Iss 3, p e0282512 (2023)
Triple Negative Breast Cancer (TNBC), a subtype of breast cancer, has fewer successful therapeutic therapies than other types of breast cancer. Insulin-like growth factor receptor 1 (IGF1R) and the Insulin receptor (IR) are associated with poor outco
Externí odkaz:
https://doaj.org/article/b9644b158fb94f80a2b68dadca1eef19
Publikováno v:
Endocrinology, Diabetes & Metabolism Case Reports, Vol 1, Iss 1, Pp 1-5 (2021)
Thyroid dysfunction is among the most common immune-related adverse reactions associated with immune checkpoint inhibitors. It most commonly manifests as painless thyroiditis followed by permanent hypothyroidism. This usually causes mild toxicity tha
Externí odkaz:
https://doaj.org/article/a8782f670e944570ab43bf3926267c00
Autor:
Peter Schmid, Marie-Paule Sablin, Jonas Bergh, Seock-Ah Im, Yen-Shen Lu, Noelia Martínez, Patrick Neven, Keun Seok Lee, Serafín Morales, J. Alejandro Pérez-Fidalgo, Douglas Adamson, Anthony Gonçalves, Aleix Prat, Guy Jerusalem, Laura Schlieker, Rosa-Maria Espadero, Thomas Bogenrieder, Dennis Chin-Lun Huang, John Crown, Javier Cortés
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-11 (2021)
Abstract Background Xentuzumab—a humanised IgG1 monoclonal antibody—binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling and suppressing AKT activation by everolimus. This phase Ib/II exploratory trial evaluated xentuzumab plus eve
Externí odkaz:
https://doaj.org/article/1117dc67dd994a8f8f4c31719c73a41f